RT team
The Indian pharmaceutical sector is on the brink of a transformative shift, with advancements in AI, machine learning, and precision medicine poised to revolutionize drug discovery, manufacturing, and patient care. By 2030, the industry is projected to nearly double in size, reaching USD 130 billion, driven by innovation, global reach, and enhanced quality standards.
Currently contributing 20% to the global generic drug market, Indian pharma is leveraging its demographic and digital talent to establish itself as a global hub for affordable, high-quality pharmaceuticals. Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance (IPA), highlighted the pivotal role of innovation, backed by supportive policies and private-sector initiatives, in achieving this vision.
The government’s forthcoming Research & Innovation Programme is expected to catalyze breakthroughs in areas such as CAR-T cell therapy, mRNA vaccines, and complex molecule development. Additionally, the impending patent expirations of major biologics by 2025 open significant opportunities in the global biosimilars market.
Private-sector players, including Sun Pharma and Dr. Reddy’s Laboratories, are intensifying their focus on specialty drugs and high-value portfolios. Meanwhile, Anil Matai, Director General of the Organisation of Pharmaceutical Producers of India (OPPI), emphasized the role of strengthened regulatory frameworks in accelerating the adoption of innovative therapies while ensuring patient safety.
Collaboration among policymakers, academia, and industry stakeholders remains key to addressing unmet medical needs, particularly in underserved regions. This collective effort will position India as a leader in global healthcare innovation and pharmaceutical excellence.
